Letter | Published: 07 August 2020

Chronic myeloproliferative neoplasms

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Onima Chowdhury, Jennifer O'Sullivan, Nikolaos Barkas, Guanlin Wang, Gemma Buck, Angela Hamblin, Ayalew Tefferi, Haifa K. Al-Ali, Giovanni Barosi, Timothy Devos, Heinz Gisslinger, Qian Jiang, Jean-Jacques Kiladjian, Ruben Mesa, Francesco Passamonti, Vincent Ribrag, Gary Schiller, Alessandro M. Vannucchi, Daobin Zhou, Mary Frances McMullin, Jianhua Zhong, Robert Peter Gale & Adam J. Mead ✉ for the RESUME trialists

Leukemia (2020)

References

1. Tefferi A. Anemia in myelofibrosis-prevalence, the U2AF1 connection, new treatments. Blood Cancer J. 2017;7:648.

2. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123–33.

3. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861.

4. Tefferi A, M. Finke C, Lasho T, A. Hanson C, Ketterling R, Gangat N, et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia. 2018;32:2274–8.

5. Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-

associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017;31:1252.

6. **6.** Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1:105–11.

7. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299–307.

8. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts. N. Engl J Med. 2011;365:1384–95.

9. Shirai Cara L, Ley James N, White Brian S, Kim S, Tibbitts J, Shao J, et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell. 2015;27:631–43.

10. Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS, et al. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 2020;34:799–810.

11. Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32:1631–42.

12. Jonasova A, Bokorova R, Polak J, Vostry M, Kostecka A, Hajkova H, et al. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Eur J Haematol. 2015;95:27–34.

Acknowledgements

Supported in part by a National Institute for Health Research (NIHR) academic clinical lectureship (OC), the John Fell Fund, a Medical Research Council Senior Clinical Fellowship (AJM, MR/l006340/1), a Cancer Research UK (CRUK) Senior Cancer Research Fellowship. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. Supported in part by an unrestricted educational grant from Celgene Corp.

RESUME trialist

John Catalano[18], William Stevenson[19], Günther Gastl[20], Werner Linkesch[21], Jan Van Droogenbroeck[22], Philippe Mineur[23], Vikas Gupta[24], Andrew Turner[25], Thomas Nevill[26], Jianyong Li[27], Zhixiang Shen[28], Ting Liu[29], Dominique Bordessoule[30], Shanti Natarajan-Amé[31], Christian Recher[32], Jean Loup Demory[33], Richard Schlenk[34], Martin Griesshammer[35], Mario Cazzola[36], Giuseppe Saglio[37], Giorgina Specchia[38], Alessandro Rambaldi[39], Fabrizio Pane[40], Sonja Zweegman[41], Peter te Boekhorst[42], Reinier Raymakers[43], Kudrat Abdulkadyrov[44], Manana Sokolova[45], Galina Salogub[46], Andrey Zaritskiy[47], Francisco Cervantes[48], Juan Carlos Hernández Boluda[49], Emilio Ojeda[50], Daniel Tesfa[51], Lars Nilsson[52], Mark Drummond[53], John Reilly[54], Claire Harrison[55], Dragana Milojkovic[56], Candido Rivera[57], Emmanuel Besa[58], H. Joachim Deeg[59], John Mascarenhas[60], Josef Prchal[61], Ramon Tiu[62], Moshe Talpaz[63], Jen Chin Wang[64], Raajit Rampal[65], Damiano Rondelli[66], Kelly McCaul[67], Randall Brown[68], Norio Komatsu[69], Kazuma Ohyashiki[70], Kiyoshi Ando[71], Hiroshi Kawabata[72], Katsuto Takenaka[73], Tomoko Hata[74], James Vardiman[75]

Author information

Affiliations

1. NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK

   Onima Chowdhury, Jennifer O'Sullivan, Nikolaos Barkas, Guanlin Wang, Gemma Buck, Angela Hamblin & Adam J. Mead

2. Mayo Clinic, Rochester, MN, USA

   Ayalew Tefferi

3. University Hospital Halle, Halle, Germany

   Haifa K. Al-Ali

4. Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

   Giovanni Barosi

5. Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), Leuven, Belgium

   Timothy Devos

6. Medizinische Universität Wien, Vienna, Austria

   Heinz Gisslinger

7. Peking University, People's Hospital, Beijing, China

   Qian Jiang

8. Hôpital Saint-Louis, Paris, France

Jean-Jacques Kiladjian

9. Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA

   Ruben Mesa

10. University of Insubria, Varese, Italy

    Francesco Passamonti

11. Cancer Campus, 11 Gustave Roussy, Villejuif, France

    Vincent Ribrag

12. Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Gary Schiller

13. Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

    Alessandro M. Vannucchi

14. Peking Union Medical College Hospital, Beijing, China

    Daobin Zhou

15. Queens University Belfast, Belfast, UK

    Mary Frances McMullin

16. Bristol-Myers Squibb, New Brunswick, NJ, USA

    Jianhua Zhong

17. Haematology Research Centre, Imperial College London, London, UK

    Robert Peter Gale

18. Oncology Day Unit, Frankston Hospital, Frankston, VIC, Australia

    John Catalano

19. Royal North Shore Hospital, St Leonards, NSW, Australia

    William Stevenson

20. Medizinische Universität Innsbruck, Innsbruck, Austria

    Günther Gastl

21. Medizinische Universität Graz, Graz, Austria

    Werner Linkesch

22. Academisch Ziekenhuis Brugge, Brugge, Belgium

    Jan Van Droogenbroeck

23. Grand Hôpital de Charleroi, Charleroi, Belgium

    Philippe Mineur

24. Princess Margaret Hospital, Toronto, Canada

Vikas Gupta

25. Department of Medical Oncology, Cross Cancer Institute, Toronto, ON, Canada

    Andrew Turner

26. Vancouver General Hospital, Toronto, ON, Canada

    Thomas Nevill

27. Jiangsu Province Hospital, Nanjing, China

    Jianyong Li

28. Shanghai Ruijin Hospital, Shanghai, China

    Zhixiang Shen

29. West China Hospital, Sichuan University, Chengdu, China

    Ting Liu

30. Centre Hospitalier Universitaire Limoges, Limoges, France

    Dominique Bordessoule

31. Centre Hospitalier Universitaire de Strasbourg - Hôpital Civil, Strasbourg, France

    Shanti Natarajan-Amé

32. Hôpital Purpan, Toulouse, Service Hématologie, Toulouse, France

    Christian Recher

33. Groupe Hospitalier de l’Institue Catholique de Lille-Hôpital Saint-Vincent de Paul (Belfort), Lille, France

    Jean Loup Demory

34. Universitätsklinik Ulm, Ulm, Germany

    Richard Schlenk

35. Johannes-Wesling-Klinikum Minden, Minden, Germany

    Martin Griesshammer

36. Fondazione IRCCS Policlinico S. Matteo, Pavia PV, Italy

    Mario Cazzola

37. Azienda Ospedaliero-Univesitaria ‘San Luigi Gonzaga’, Bergamo, Italy

    Giuseppe Saglio

38. Azienda Ospedaliera Policlinico di Bari, Bergamo, Italy

    Giorgina Specchia

39. Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

    Alessandro Rambaldi

40. Azienda Ospedaliera Universitaria ‘Federico II’, Naples, Italy

    Fabrizio Pane

41. VU University Medical Centre, Amsterdam, the Netherlands

    Sonja Zweegman

42. Erasmus Medisch Centrum, Rotterdam, the Netherlands

    Peter te Boekhorst

43. Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands

    Reinier Raymakers

44. FGU Russian Scientific Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia

    Kudrat Abdulkadyrov

45. Hematology Scientific Center, Moscow, Russia

    Manana Sokolova

46. SaintPetersburg I.P. Pavlov State Medical University, Saint Petersburg, Russia

    Galina Salogub

47. FSI 'V.A. Almazov Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies', Saint Petersburg, Russia

    Andrey Zaritskiy

48. Hospital Clinic I Provincial de Barcelona, Barcelona, Spain

    Francisco Cervantes

49. Hospital Clinico Universitario de Valencia, Valencia, Spain

    Juan Carlos Hernández Boluda

50. Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain

    Emilio Ojeda

51. Karolinska University Hospital Huddinge, Solna, Sweden

    Daniel Tesfa

52. Skånes Universitetssjukhus i Lund, Lund, Sweden

    Lars Nilsson

53. Beatson Oncology Centre, Glasgow, UK

    Mark Drummond

54. Royal Hallamshire Hospital, Sheffield, UK

    John Reilly

55. Guy’s Hospital, London, UK

    Claire Harrison

56. London Hammersmith Hospital, London, UK

    Dragana Milojkovic

57. Mayo Clinic, Jacksonville, FL, USA

Candido Rivera

58. Jefferson Medical College, Philadelphia, PA, USA

    Emmanuel Besa

59. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    H. Joachim Deeg

60. Mount Sinai Hospital, The Donald H Ruttenberg Cancer Treatment Center, New York, NY, USA

    John Mascarenhas

61. University of Utah Health Sciences Center, Salt Lake City, USA

    Josef Prchal

62. The Cleveland Clinic Foundation, Cleveland, OH, USA

    Ramon Tiu

63. University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Moshe Talpaz

64. Brookdale Hospital Medical Center, New York, NY, USA

    Jen Chin Wang

65. Memorial Sloan- Kettering Cancer Center, New York, NY, USA

    Raajit Rampal

66. University of Illinois at Chicago, Chicago, IL, USA

    Damiano Rondelli

67. Avera Hematology and Transplant, Sioux Falls, SD, USA

    Kelly McCaul

68. University of Florida Shands Cancer Center, Gainesville, FL, USA

    Randall Brown

69. Juntendo University Hospital, Bunkyo, Japan

    Norio Komatsu

70. Tokyo Medical University Hospital, Shinjuku, Japan

    Kazuma Ohyashiki

71. Tokai University Hospital, Shibuya, Japan

    Kiyoshi Ando

72. Kyoto University Hospital, Kyoto, Japan

    Hiroshi Kawabata

73. Kyushu University Hospital, Fukuoka, Japan

    Katsuto Takenaka

74. Nagasaki University Hospital, Nagasaki, Japan

Tomoko Hata

75. University of Chicago, Chicago, Japan

James Vardiman

Consortia

for the RESUME trialists

- John Catalano
- , William Stevenson
- , Günther Gastl
- , Werner Linkesch
- , Jan Van Droogenbroeck
- , Philippe Mineur
- , Vikas Gupta
- , Andrew Turner
- , Thomas Nevill
- , Jianyong Li
- , Zhixiang Shen
- , Ting Liu
- , Dominique Bordessoule
- , Shanti Natarajan-Amé
- , Christian Recher
- , Jean Loup Demory
- , Richard Schlenk
- , Martin Griesshammer
- , Mario Cazzola
- , Giuseppe Saglio
- , Giorgina Specchia
- , Alessandro Rambaldi
- , Fabrizio Pane

- , Sonja Zweegman
- , Peter te Boekhorst
- , Reinier Raymakers
- , Kudrat Abdulkadyrov
- , Manana Sokolova
- , Galina Salogub
- , Andrey Zaritskiy
- , Francisco Cervantes
- , Juan Carlos Hernández Boluda
- , Emilio Ojeda
- , Daniel Tesfa
- , Lars Nilsson
- , Mark Drummond
- , John Reilly
- , Claire Harrison
- , Dragana Milojkovic
- , Candido Rivera
- , Emmanuel Besa
- , H. Joachim Deeg
- , John Mascarenhas
- , Josef Prchal
- , Ramon Tiu
- , Moshe Talpaz
- , Jen Chin Wang
- , Raajit Rampal
- , Damiano Rondelli
- , Kelly McCaul
- , Randall Brown
- , Norio Komatsu
- , Kazuma Ohyashiki
- , Kiyoshi Ando

- , Hiroshi Kawabata
- , Katsuto Takenaka
- , Tomoko Hata
- & James Vardiman

Contributions

OC designed and analyzed experiments and prepared the typescript; JO performed the statistical analysis and contributed to preparing the typescript. NB and GW performed bioinformatic analysis; GB designed the sequencing panels, processed samples, and performed experiments; AH contributed to the design of the panels and advised on data analyses; AT, HKA, GB, TD, HG, QJ, J-JK, RM, FP, VR, GS, AMV, DZ, MFM, and JZ contributed samples. RPG supervised the project and helped prepare the typescript. AJM conceived and supervised the project, designed experiments and helped prepare the typescript. All authors read and approved the typescript.

Corresponding author

Correspondence to Adam J. Mead.

Ethics declarations

Conflict of interest

GS has participated in speakers bureau and received research funding from Celgene. MFM has participated in advisory boards and speakers bureaus for Celgene and Novartis. AJM has participated in advisory boards and speakers bureaus for Celgene and Novartis.

Additional information

Members of the RESUME trialists are listed below Acknowledgements.

Supplementary information

Supplemental Materials and Methods
Supplemental Table 1
Supplemental Table 2
Supplemental Table 3

Rights and permissions

About this article

Cite this article

Chowdhury, O., O'Sullivan, J., Barkas, N. *et al.* Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. *Leukemia* (2020). https://doi.org/10.1038/s41375-020-0979-6

Received 19 April 2020 **Revised** 30 June 2020 **Accepted** 07 July 2020

Published 07 August 2020 **DOI** https://doi.org/10.1038/s41375-020-0979-6

Subjects Genetics research • Myeloproliferative disease

Further reading

- ** Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data **
  Giuseppe G Loscocco, Paola Guglielmelli & Alessandro M Vannucchi

  OncoTargets and Therapy (2020)

Leukemia ISSN 1476-5551 (online)